Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection

Article Abstract:

CD4 cell counts may not be accurate indicators of drug effectiveness in clinical trials of didanosine (ddI) and zalcitabine (ddC) for the treatment of HIV infection. CD4 counts are thought to indicate prognosis for HIV-infected people and they are often used in trials as a short-term indicator of long-term outcome, such as disease progression or death. Researchers analyzed the data from a trial comparing treatment with ddI andddC in 467 HIV-infected people. CD4 counts rose in the first 2 months of treatment with ddI but not ddC, and then fell slowly over the next 16 months in both groups. However, with ddI, disease progression and survival were not correlated with response of CD4 counts to treatment. On the other hand, with ddC, response of CD4 counts did correlate with disease progression and survival.

Methods, Evaluation, Measurement, Clinical trials, CD4 lymphocytes, Didanosine, Zalcitabine

---

Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: Final Results of the CPCRA 064 study

Article Abstract:

The final results of Community Programs are reported for Clinical Research on AIDS (CPCRA-64) study, a multicenter, prospective, randomized, controlled trial that determines the long-term clinical impact of structured treatment interruption (STI) in multidrug-resistant (MDR) HIV-1 patients. Prior to changing regimens in patients with MDR HIV-1 treatment failure has a prolonged negative impact on CD4 cell count recovery and does not confer progression of disease or virologic benefits.

United States, Management dynamics, Care and treatment, Management, Company business management, AIDS treatment, Clinical report

---

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus

Article Abstract:

Telling HIV patients to stop taking their drugs for a few months may not benefit them at all, according to a study of 270 patients. This is often suggested to prevent the virus from becoming resistant to the drugs. However, in this study, patients who stopped taking the drugs for four months were more than twice as likely to get more sick and even to die than patients who continued taking the drugs.

Prevention, Drug resistance in microorganisms, Microbial drug resistance

Similar abstracts:

• Abstracts: The clinical spectrum of hepatitis C virus in HIV coinfection. New centers for disease control and prevention's guidelines on HIV counseling and testing for the general population and pregnant women
• Abstracts: T cell-encoded CD80 and 4-1 BBL induce auto- and transcostimulation, resulting in potent tumor rejection
• Abstracts: Immune thrombocytopenic purpura -- let the treatment fit the patient. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.